Supplementary materials: The cost–effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark

<b>These are peer-reviewed supplementary material for the article ‘</b><b>The cost–effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark’ </b><b>published in the </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Table S1</b>: Baseline Characteristics.<b>Table S2</b>: Treatment Effects – First Line.<b>Table S3</b>: Adverse Events.<b>Table S4</b>: Treatment effects for second/third line treatments (treatment policy estimand).<b>Table S5</b>: Proportion of patients on preventive medication.<b>Table S6</b>: Screening and patient management proportions.<b>Table S7</b>: Sensitivity and specificity of tests.<b>Table S8</b>: Annual treatment costs applied (DKK, AIP 2020, [20]).<b>Table S9</b>: Cost Inputs for the CDM (Costs inflated to 2020 values, DKK).<b>Table S10</b>: Utilities used in CDM.<b>Table S11</b>: Scenario analysis results.<b>Table S12</b>: Breakdown of costs (DKK, per average patient).<b>Summary: </b><b>Aim:</b> To evaluate the cost–effectiveness of oral semaglutide+metformin versus empagliflozin+metformin in people with Type 2 diabetes uncontrolled on msetformin alone. <b>Materials and methods:</b> The IQVIA Core Diabetes Model was populated with efficacy data from a head-to-head study between oral semaglutide+metformin and empagliflozin+metformin. Danish costs and quality-of-life data were sourced from literature. Price per day was Danish Krone (DKK) 25.53 for oral semaglutide and DKK11.40 for empagliflozin. Discounting was fixed at 4%. Scenario and sensitivity analyses were performed. <b>Results:</b> Over a lifetime, Core Diabetes Model projected 8.78 and 8.75 quality-adjusted life-years and a total cost of DKK 447,633 and DKK 387,786, thereby generating an incremental cost–effectiveness ratio of DKK 1,930,548 for oral semaglutide+metformin versus empagliflozin+metformin. Scenario and sensitivity analyses showed the robustness of the outcomes. Duration of treatment with oral semaglutide is the key driver of the analyses. <b>Conclusion:</b> Oral semaglutide+metformin seems not cost effective versus empagliflozin+metformin in patients uncontrolled on metformin in Denmark.